Uniphar PLC
LSE:UPR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its 3-Year Average (26.8), the stock would be worth GBX314.23 (11% downside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 30.1 | GBX353 |
0%
|
| 3-Year Average | 26.8 | GBX314.23 |
-11%
|
| 5-Year Average | 26.8 | GBX314.23 |
-11%
|
| Industry Average | 27.5 | GBX323.52 |
-8%
|
| Country Average | 18.7 | GBX219.31 |
-38%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| IE |
U
|
Uniphar PLC
LSE:UPR
|
1.1B GBP | 30.1 | 20.8 | |
| US |
|
Mckesson Corp
NYSE:MCK
|
100.3B USD | 10.6 | 23.1 | |
| US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
60.7B USD | 18.4 | 37.4 | |
| US |
|
Cencora Inc
NYSE:COR
|
59.9B USD | 18.2 | 36.9 | |
| US |
|
Cardinal Health Inc
NYSE:CAH
|
45.5B USD | 9.3 | 27.4 | |
| AU |
|
Sigma Healthcare Ltd
ASX:SIG
|
32.1B AUD | 62.6 | 35.4 | |
| CN |
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
62.8B CNY | 19.7 | 11.1 | |
| CN |
|
Huadong Medicine Co Ltd
SZSE:000963
|
58.8B CNY | 158.3 | 20.6 | |
| US |
|
Henry Schein Inc
NASDAQ:HSIC
|
8.6B USD | 22.2 | 21.7 | |
| KR |
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW | -285 | 89.6 | |
| CN |
|
Sinopharm Group Co Ltd
HKEX:1099
|
58.6B HKD | 0.5 | 7.2 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13 |
| Median | 18.7 |
| 70th Percentile | 27.5 |
| Max | 2 454.8 |
Other Multiples
Uniphar PLC
Glance View
Uniphar Plc engages in the provision of pre-wholesale and wholesale pharmaceutical distribution. The company is headquartered in Dublin, Dublin and currently employs 2,920 full-time employees. The company went IPO on 2019-07-17. The firm is a diversified healthcare services company. The company serves multinational pharmaceutical and medical technology manufacturers across three divisions: Commercial & Clinical, Product Access and Supply Chain & Retail. Through commercial & clinical division, the Company provides sales, marketing and distribution solutions to multinational pharmaceutical and medical device manufacturers on an outsourced basis. Product Access division offers two service offerings: On Demand Access and Exclusive Access. On Demand Access is a pharmacy led solutions for sourcing and supplying unlicensed medicines to meet the needs of both retail and hospital pharmacists. Exclusive Access is a manufacturer led solution for controlling the release of specialty medicines for specifically approved patient populations. Supply Chain & Retail provides both pre-wholesale distribution and wholesale distribution of pharmaceutical, healthcare and animal health products.
